欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (1): 56-62.doi: 10.12092/j.issn.1009-2501.2022.01.008

• 临床药理学 • 上一篇    下一篇

苯磺酸氨氯地平片在中国健康受试者中的生物等效性研究

高茸,马亚中,赵海霞,王肇源,张伟红,袁海龙   

  1. 中国人民解放军空军特色医学中心药学部,北京 100142
  • 收稿日期:2021-05-24 修回日期:2022-01-18 出版日期:2022-01-26 发布日期:2022-02-09
  • 通讯作者: 袁海龙,男,博士,主任药师,主要从事临床药学与药物临床试验相关工作。 Tel: 66928505 E-mail: yhlpharm@126.com
  • 作者简介:高茸,女,博士,主管药师,主要从事临床药学与药物临床试验相关工作。 Tel: 66928501 E-mail: gaorong_07@163.com
  • 基金资助:
    国家自然科学基金(81903680)

Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects

GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong   

  1. Department of Pharmacy, Air Force Medical Center, PLA, Beijing 100142, China
  • Received:2021-05-24 Revised:2022-01-18 Online:2022-01-26 Published:2022-02-09

摘要: 目的:在空腹和餐后条件下,评价两种苯磺酸氨氯地平片在中国健康受试者中的生物等效性。方法:入组24例健康受试者,采用随机、开放、两周期自身交叉试验设计,分别在空腹和餐后条件下给予受试制剂或参比制剂,用液质联用法(LC-MS/MS)测定给药后氨氯地平的血浆浓度,计算主要药代动力学参数,评价受试制剂与参比制剂的生物等效性。结果:健康受试者在空腹口服氨氯地平片后,受试制剂和参比制剂Cmax、AUC0-t、AUC0-∞的均值分别为(3 462.08±683.46) pg/mL、(159 891.00±45 951.00)pg·mL-1·h、(194 850.00±63 829.00) pg·mL-1·h和(3 346.09±710.09) pg/mL、(159 065.00±45 214.00) pg·mL-1·h、(190 461.00±66 160.00) pg·mL-1·h;几何均值的比值及其90%置信区间分别为104.82%(100.35%,109.50%)、103.32%(98.13%,108.78%)、103.98%(97.95%,110.38%)。餐后服用盐酸氨氯地平片后,受试制剂和参比制剂Cmax、AUC0-t、AUC0-∞的均值分别为(2 785.00±600.91) pg/mL、(138 289.00±30 684.00) pg·mL-1·h、(158 765.00±39 260.00) pg·mL-1·h和(2 960.00±671.27) pg/mL、(140 990.00±33 326.00) pg·mL-1·h、(163 996.00±43 606.00) pg·mL-1·h;几何均数的比值及其90%置信区间分别为94.89%(88.94%,101.23%)、97.96%(92.85%,103.34%)、97.26%(91.61%,103.25%)。结论:在空腹和餐后状态下受试制剂和参比制剂的吸收速度和程度均一致,两制剂生物等效,同时两制剂在中国健康受试人群中具有相似的安全性和耐受性。

关键词: 氨氯地平, 健康志愿者, 液质联用, 生物等效

Abstract: AIM: To evaluate the bioequivalence of two kinds of amlodipine besylate tablets in Chinese healthy subjects under fasting and fed conditions. METHODS: Twenty-four healthy subjects were enrolled, and a random, open, single-dose, two preparations, two sequences and double-crossover design was used to give the test or reference preparations under fasting and postprandial conditions. The concentration of metformin in plasma was detected by LC-MS/MS, and the main pharmacokinetic parameters were calculated to evaluate the bioequivalence. RESULTS: In fasting state, the mean of Cmax, AUC0-t, and AUC0-∞ of the test and reference preparations was (3 462.08±683.46) pg/mL, (159 891.00±45 951.00) pg·mL-1·h, (194 850.00±63 829.00) pg·mL-1·h, (3 346.09±710.09) pg/mL, (159 065.00±45 214.00) pg·mL-1·h, (190 461.00±66 160.00) pg·mL-1·h, respectively. The ratio of geometric mean and its 90% confidence interval are 104.82% (100.35%, 109.50%), 103.32% (98.13%, 108.78%), 103.98% (97.95%, 110.38%). In fed condition, the mean of Cmax, AUC0-t, and AUC0-∞ of the test and reference preparations was (2 785.00±600.91) pg/mL, (138 289.00±30 684.00) pg·mL-1·h, (158 765.00±39 260.00) pg·mL-1·h, (2 960.00±671.27) pg/mL, (140 990.00±33 326.00) pg·mL-1·h, (163 996.00±43 606.00) pg·mL-1·h, respectively. The ratio of geometric mean and its 90% confidence interval are 94.89% (88.94%, 101.23%), 97.96% (92.85%, 103.34%) and 97.26% (91.61%, 103.25%). CONCLUSION: Two kinds of amlodipine besylate tablets are bioequivalent, and have similar safety and tolerability in Chinese healthy subjects.

Key words: amlodipine, healthy volunteers, LC-MS/MS, bioequivalence

中图分类号: